BioMarck Pharmaceuticals has licensed worldwide exclusive rights for this patent and related patents from North Carolina State University. The new patent provides broad protection for a series of first-in-class mucus inhibiting peptides and the methods of treatment for a variety of pulmonary diseases involving mucus hypersecretion. A European patent and a series of international patents are allowed while others are pending.
Indu Parikh, BioMarck’s president and chief scientific officer, said: “BioMarck believes that this patent significantly strengthens its overall intellectual property portfolio. Our treatment is designed to address a variety of pulmonary diseases, including chronic obstructive pulmonary disease, asthma and chronic rhinitis, and possibly sinusitis and cystic fibrosis. Each of these market segments has clear needs for a new and effective drug.”